风险因素和预测酸诱导肝损伤的诺米克图:一个嵌套的病例对照研究
Yue Chen1, Yadong Wang2, Runan Xia3
1School of Pharmacy, Anhui Medical University, Hefei, China; Department of Pharmacy, Lu'an People's Hospital, Lu'an, China.
Biomolecules & biomedicine
|December 5, 2024
概括
瓦尔酸 (VPA) 可以导致肝损伤. 关键的危险因素包括失糖症,高脂血症,手术和低血糖症. 一个新的诺莫格拉姆模型有助于预测VPA诱导的肝损伤风险.
科学领域:
- 药物监督 药物监督 药物监督
- 肝病学 肝病学是一种肝病学.
- 临床药理学 临床药理学
背景情况:
- 瓦尔酸 (VPA) 广泛使用,但具有肝损伤的风险,风险因素不明.
- 目前的临床实践缺乏一种工具来识别易受VPA诱导肝损伤的患者.
研究的目的:
- 调查与酸诱导的肝损伤 (VILI) 相关的风险因素.
- 为VILI.开发和验证一个预测名ogram模型.
主要方法:
- 对接受VPA治疗的患者 (2020-2023) 的医学数据的回顾性分析.
- 使用处方序列分析识别疑似VILI病例.
- 通过罗塞尔·乌克拉夫因果关系评估方法进行因果关系评估.
- 后勤回归用于风险因素分析和名图开发.
主要成果:
- 该研究包括256名患者 (64名VILI,192名对照),总体VILI发病率为5.3%.
- 确定了VILI的独立危险因素:失糖症 (OR=5.171),高脂血症 (OR=4.903),手术 (OR=10.020) 和低血糖症 (OR=10.407).
- 开发的名图表显示出出色的预测性能 (AUC=0.904) 和准确性.
结论:
- 低血糖,高脂血症,之前的手术和低血糖是VILI的重要危险因素.
- 经过验证的诺莫格拉姆模型提供了一个可靠的工具,用于预测在接受瓦尔酸的患者中VILI风险.
更多相关视频
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.2K
09:44Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
9.9K
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
120
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
120
Probability Laws
40.1K
Overview
40.1K
